Clinical trial
Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
NCT01373333 is registered in ClinicalTrials.gov with The Cleveland Clinic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
- Lead sponsor
- The Cleveland Clinic
- Phase
- Expanded access
- Overall status
- No longer available
- Start date
- September 30, 1997
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.